Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Unknown 17Recruiting 6Withdrawn 3Terminated 3Active not recruiting 3Not yet recruiting 2Completed 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Gastrointestinal 1

Conditions

Glioma 2Simpson-Golabi-Behmel syndrome 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Immunotherapy, Adoptive × Clear all
NCT02575261 2020-07-16

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
CNS

Glioma

NCT02723942 2020-07-16

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
Gastrointestinal

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT03252171 2020-07-16

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Withdrawn
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡